NCT00849550View on ClinicalTrials.gov

Safety and Dosage Study of RAD001 (Everolimus) in Combination With Current Standard of Care to Treat Advanced Solid Tumors.

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

July 31, 2009

Primary Completion Date

December 31, 2012

Study Completion Date

December 31, 2012

Conditions
Unspecified Adult Solid Tumor, Protocol SpecificCancer
Interventions
DRUG

capecitabine/oxaliplatin/bevacizumab/RAD001 (XELOX-A-Ev)

bevacizumab IV, capecitabine oral, oxaliplatin IV, RAD001 oral

Trial Locations (3)

27710

Duke University Medical Center, Durham

37203

Sarah Cannon Research Institute, Nashville

60426

Ingalls Cancer Research Center, Harvey

Sponsors

Collaborators (1)

Novartis
All Listed Sponsors
collaborator

Roche-Genentech

INDUSTRY

collaborator

Novartis

INDUSTRY

lead

Herbert Hurwitz

OTHER

NCT00849550 - Safety and Dosage Study of RAD001 (Everolimus) in Combination With Current Standard of Care to Treat Advanced Solid Tumors. | Biotech Hunter | Biotech Hunter